Research programme: small molecule therapeutics- Daewoong Pharmaceutical/Salipro Biotech
Latest Information Update: 04 Jul 2025
At a glance
- Originator Daewoong Pharmaceutical; Salipro Biotech
- Class Small molecules
- Mechanism of Action Membrane protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Unspecified
Most Recent Events
- 11 Jun 2025 Salipro Biotech collaborates with Daewoong Pharmaceutical to develop small molecule therapeutics against membrane protein targets
- 11 Jun 2025 Early research in Unspecified in South Korea (unspecified route), prior to June 2025
- 11 Jun 2025 Early research in Unspecified in Sweden (unspecified route), prior to June 2025